SCHEMBL87709

SCHEMBL87709

C=CCOP(N)(=O)OCC=C

nearest known ligand 0.31

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
LPAR2 Q9HBW0 1/20 0.31
LPAR3 Q9UBY5 1/20 0.31
ALDH1A1 P00352 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9296108 0.87
SCHEMBL6273596 0.85
SCHEMBL10932944 0.83
SCHEMBL87710 0.79
SCHEMBL30605 0.77 TSHR (0.38) LPAR2LPAR3ALDH1A1
SCHEMBL31694471 0.74 BTN3A1 (0.36)
SCHEMBL3507987 0.74 CYP3A4 (0.32) LPAR2LPAR3ALDH1A1
SCHEMBL9570202 0.74 LPAR2 (0.32) LPAR2LPAR3ALDH1A1
SCHEMBL14061859 0.74 MAPT (0.31)
SCHEMBL10384660 0.74 ALDH1A1 (0.32) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4399208-A1 IRAK INHIBITOR FOR TREATING CYTOKINE RELEASE-RELATED CONDITIONS ASSOCIATED WITH INFECTION BY A RESPIRATORY VIRUS Rigel Pharmaceuticals, Inc. (US) 2024-07-17 EP claimed
CN-114686574-B Method and kit for detecting nucleotide large fragment deletion 厦门大学 2024-07-02 CN claimed
US-11788118-B2 Method for detecting target nucleic acid sequences XIAMEN ZEESAN BIOTECH CO., LTD. (CN) 2023-10-17 US claimed
CN-111100862-B Method for detecting bacterial serotypes 厦门大学 2023-09-29 CN claimed
US-20230303555-A1 PYRIMID-2-YL-PYRAZOLE COMPOUNDS AS IRAK INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2023-09-28 US claimed
WO-2023183377-A1 PYRIMID-2-YL-PYRAZOLE COMPOUNDS AS IRAK INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2023-09-28 WO claimed
WO-2023038815-A1 IRAK INHIBITOR FOR TREATING CYTOKINE RELEASE-RELATED CONDITIONS ASSOCIATED WITH INFECTION BY A RESPIRATORY VIRUS RIGEL PHARMACEUTICALS, INC. (US) 2023-03-16 WO claimed
EP-3640340-B1 METHOD FOR DETECTING TARGET NUCLEIC ACID SEQUENCES XIAMEN ZEESAN BIOTECH CO LTD (CN) 2022-06-29 EP claimed
EP-4003990-A1 PYRAZOLE COMPOUNDS, FORMULATIONS THEREOF, AND A METHOD FOR USING THE COMPOUNDS AND/OR FORMULATIONS Rigel Pharmaceuticals, Inc. (US) 2022-06-01 EP claimed
CN-114364674-A Pyrazole compounds, formulations thereof, and methods of using the compounds and/or formulations 里格尔药品股份有限公司 2022-04-15 CN claimed
WO-2021041898-A1 PYRAZOLE COMPOUNDS, FORMULATIONS THEREOF, AND A METHOD FOR USING THE COMPOUNDS AND/OR FORMULATIONS RIGEL PHARMACEUTICALS, INC. (US) 2021-03-04 WO claimed
US-20210061798-A1 PYRAZOLE COMPOUNDS, FORMULATIONS THEREOF, AND A METHOD FOR USING THE COMPOUNDS AND/OR FORMULATIONS RIGEL PHARMACEUTICALS, INC. (US) 2021-03-04 US claimed
US-20200140931-A1 METHOD FOR DETECTING TARGET NUCLEIC ACID SEQUENCES XIAMEN ZEESAN BIOTECH CO., LTD. (CN) 2020-05-07 US claimed
EP-3640340-A1 METHOD FOR DETECTING TARGET NUCLEIC ACID SEQUENCES Xiamen University (CN) 2020-04-22 EP claimed
EP-2344447-A2 GABA CONJUGATES AND METHODS OF USE THEREOF Kyphia Pharmaceuticals, Inc. (US) 2011-07-20 EP claimed
WO-2010042759-A2 GABA CONJUGATES AND METHODS OF USE THEREOF KYPHIA PHARMACEUTICALS INC (US) 2010-04-15 WO claimed
US-7667033-B2 Compositions and methods for the use of FMOC derivatives in DNA/RNA synthesis SYNGEN, INC. (US) 2010-02-23 US claimed
US-20090171076-A1 COMPOSITIONS AND METHODS FOR THE USE OF FMOC DERIVATIVES IN DNA/RNA SYNTHESIS SYNGEN, INC. 2009-07-02 US claimed
US-20080098643-A1 Ethanol modifier and its application HOU JINPENG 2008-05-01 US claimed
US-20070179289-A1 Compositions and methods for the use of FMOC derivatives in DNA/RNA synthesis SYNGEN, INC. 2007-08-02 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210061798-A1 PYRAZOLE COMPOUNDS, FORMULATIONS THEREOF, AND A METHOD FOR USING THE COMPOUNDS AND/OR FORMULATIONS IRAK1, IRAK3, IRAK2 LPAR2 4059/4885LPAR3 3298/4885ALDH1A1 3780/4885
US-20230303555-A1 PYRIMID-2-YL-PYRAZOLE COMPOUNDS AS IRAK INHIBITORS IRAK2, IRAK3, IRAK1 LPAR2 1354/4885LPAR3 1581/4885ALDH1A1 1493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.